Cost of Antivirals for HIV/AIDS Set to Increase
News Apr 06, 2012
Antiviral drugs for HIV/AIDS patients will become more expensive as doctors embrace new, highly-priced combination treatments, according to a new report by pharmaceutical industry experts GBI Research.
The new report shows that, in 2002, the annual treatment for HIV/AIDS cost an average of $9,971. This grew substantially at a compound average growth rate (CAGR) of 3.2% to $12,829 in 2010.
Correspondingly, revenue from the global HIV/AIDS therapeutics market grew at a CAGR of 10.9% during 2002-2010.
The annual cost of treatment for HIV/AIDS has increased steadily over the past decade, due to the launch of new combination therapies.
One example is the new, multi-class combination drug Atripla, a form of Highly Active Anti-Retroviral Therapy (HAART).
Sales of Atripla have soared over the last three years, demonstrating a CAGR of 136%. These expensive treatments have proven their worth through impressive efficacy, particularly in patients who have developed a resistance to other HIV/AIDS drugs.
This year will see the patent expiries of key drugs such as Sustiva and Combivir, while other medications such as Epivir, Epzicom, Trizivir, Ziagen, Invirase and Lexiva went off-patent in 2009 and 2010.
However, it is thought that the impact of new generics will be partially offset by increasing use of new and more expensive drug treatments.
The HIV/AIDS therapeutics market is expanding, due to decreased mortality and increasing treatment-seeking rates, which has encouraged further pharmaceutical innovation.
Gilead filed a New Drug Application (NDA) for Quad, a combination of Gilead’s pipeline candidate Elvitegravir, Cobicistat and its currently marketed HIV drug Truvada.
Late-stage pipeline drugs Edurant and Vicriviroc are also expected to enter the market during the forecast period, and will act as future drivers for growth.
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Gut Bacteria Latest Ally in Fight Against SepsisNews
Sepsis occurs when the body's response to the spread of bacteria or toxins to the bloodstream damages tissues and organs. The fight against sepsis could get a helping hand from a surprising source: gut bacteria. Researchers found that giving mice particular microbes increased blood levels of immunoglobulin A (IgA) antibodies, which protected against the kind of widespread bacterial invasion that leads to sepsis.READ MORE